Sign Up to like & get recommendations! 2
Published in 2022 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000976
Abstract: Supplemental Digital Content is Available in the Text. Background: Ustekinumab is a recently introduced biological agent for the treatment of Crohn’s disease. The clinical use of the trough concentration of ustekinumab is not as standardized… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Clinical Psychopharmacology"
DOI: 10.1097/jcp.0000000000000913
Abstract: Background A long-acting injectable (LAI) formulation of olanzapine has been developed as an alternative to oral regimens. A therapeutic range of 20 to 80 ng/mL for oral olanzapine trough concentrations has been proposed. Here, we… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Clinical Transplantation"
DOI: 10.1111/ctr.14826
Abstract: Posaconazole is used for prophylaxis and treatment of invasive fungal infections in lung transplant recipients (LTR). Previous studies have not described the relationship between elevated posaconazole trough concentrations and adverse drug reactions in this population. read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00955-18
Abstract: Voriconazole is a broad-spectrum triazole antifungal and the first-line treatment for invasive aspergillosis (IA). The aim of this research was to study the dose adjustments of voriconazole as well as the affecting factors influencing voriconazole… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01818-17
Abstract: ABSTRACT As pharmacokinetics after burn trauma are difficult to predict, we conducted a 3-year prospective, monocentric, randomized, controlled trial to determine the extent of under- and overdosing of antibiotics and further evaluate the impact of… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190016642692
Abstract: Purpose: To determine whether there is an association between higher vancomycin trough concentrations and attainment of a calculated area under the concentration–time curve (AUC)/minimum inhibitory concentration (MIC) ≥400. Methods: A retrospective analysis was conducted among… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-017-2717-x
Abstract: BackgroundDolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Die Pharmazie"
DOI: 10.1619/ph.2019.8731
Abstract: Aim of the study: Here, we investigated the risk factors for decreased teicoplanin plasma trough concentrations relative to the initial dosing in critically ill patients. Patients and methods: Data obtained from 80 eligible critically ill… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Antibiotics"
DOI: 10.3390/antibiotics10091130
Abstract: This prospective observational study aimed to clinically describe voriconazole administrations and trough concentrations in patients with Child–Pugh class C and to investigate the variability of trough concentration. A total of 144 voriconazole trough concentrations from… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Antibiotics"
DOI: 10.3390/antibiotics12050810
Abstract: Although aminoglycosides are frequently prescribed to neonates and children, the ability to reach effective and safe target concentrations with the currently used dosing regimens remains unclear. This study aims to evaluate the target attainment of… read more here.